Big Red Tomato Packers, LLC Voluntarily Recalls Fresh Tomatoes Due to Possible Risk of Contamination from Salmonella

Big Red Tomato Packers, LLC of Fort Pierce, FL is voluntarily issuing a limited recall of 790 – 20 and 25 lb. boxes of fresh tomatoes of lot 1106, because they may have the potential to be contaminated with Salmonella. Salmonella is an organism which can cause serious infections in young children, frail or elderly people, and others with weakened immune systems.
Read The Complete Story!

Updated FDA requirements for infant formula will maintain high-quality standards and help ensure healthy growth of infants

Today, the U.S. Food and Drug Administration published an interim final rule to further safeguard the health of infants fed infant formula in the United States. The rule, which sets standards for manufacturers to produce safe infant formula that supports healthy growth, is accompanied by two draft guidance documents for industry.

FDA launches its first national public education campaign to prevent, reduce youth tobacco use

The U.S. Food and Drug Administration today announced the launch of a national public education campaign to prevent youth tobacco use and reduce the number of kids ages 12 to 17 who become regular smokers. ‘The Real Cost’ campaign is the FDA’s first of several planned tobacco education campaigns using the new authority granted under the Family Smoking Prevention and Tobacco Control Act, signed into law by President Obama in 2009.

FDA approves pediatric use of Dexcom’s G4 Platinum continuous glucose monitoring system

The U.S. Food and Drug Administration today approved the expanded use of the Dexcom G4 Platinum Continuous Monitoring System for patients with diabetes ages 2 to 17 years. The G4 Platinum System, which monitors blood glucose levels in people with diabetes, had been approved for patients ages 18 and older.

FDA Approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals

The U.S. Food and Drug Administration today approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep. This is the first FDA approval of a treatment for the disorder.